 phase trial indium anti-epiderm growth factor receptor monoclon antibodi patient squamou cell lung carcinoma murin monoclon antibodi mab epiderm growth factor egf receptor egf bind egf-induc activ receptor tyrosin kinas cell prolifer effect mab phase trial patient inoper squamou cell carcinoma lung high level egf receptor group patient total dose mab mg mg dose infus mg indium mab toxic tumor patient dose mg metastas equal cm diamet dose mg single-photon-emission-comput tomographi dose tumor visual patient anti-murin antibodi treatment mab egf receptor function safe dose schedul mab squamou cell lung carcinoma uptak label mab dose depend further studi potenti therapeut efficaci anti-egf receptor mab agent compar manner